Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core US Aggregate Bond ETF (AGG) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

iShares Core US Aggregate Bond ETF
Ginkgo Bioworks Holdings Inc

Price performance

Price movement over the last 24 hours

Key statistics

iShares Core US Aggregate Bond ETF vs Ginkgo Bioworks Holdings Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $98.05, while Ginkgo Bioworks Holdings Inc trades at $8.93 (market cap $610.13M). The key difference: Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.

AGGDNA
Sector
Fixed IncomeHealth
52-Week High
$101.40$16.14
52-Week Low
$97.63$5.48
Market Cap
$610.13M
Enterprise Value
$647.37M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core US Aggregate Bond ETF

AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.

The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.

Ginkgo Bioworks Holdings Inc

DNA trades at $10.11, down 2.79% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $312.76M on $170.16M revenue in 2025, with negative cash flow and declining revenue projected into 2026. Recent news highlights include Ginkgo Bioworks' pivot to autonomous labs and insider selling activity, while analyst consensus shows a divided outlook with 45% buy ratings.

The outlook remains challenging due to persistent losses and cash burn, though technical strength offers short-term support. Investment opportunity hinges on successful execution of the autonomous lab strategy, while risks include continued negative margins, high cash consumption, and competitive pressures in biotechnology.

Returns comparison

Trailing returns across standard periods

About iShares Core US Aggregate Bond ETF

AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.

Read more on AGG

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA